Анемия при беременности - витамины для беременных, при

реклама
Анемия при беременности
А
çÖåàü fl‚ÎflÂÚÒfl Ó‰ÌËÏ ËÁ Ò‡Ï˚ı ˜‡ÒÚ˚ı ÓÒÎÓÊÌÂÌËÈ ·ÂÂÏÂÌÌÓÒÚË. èÓ ‡Ò˜ÂÚ‡Ï ÇÒÂÏËÌÓÈ
Ó„‡ÌËÁ‡ˆËË Á‰‡‚ÓÓı‡ÌÂÌËfl [1], ‚ ‡Á‚Ë‚‡˛˘ËıÒfl ÒÚ‡Ì‡ı Ó̇ ̇·Î˛‰‡ÂÚÒfl Û 35-75% (‚ Ò‰ÌÂÏ
56%) ·ÂÂÏÂÌÌ˚ı ÊÂÌ˘ËÌ, ‡ ‚ ‡Á‚ËÚ˚ı ÒÚ‡Ì‡ı - Û
18%. ì ÏÌÓ„Ëı ËÁ ÌËı ‡ÌÂÏËfl ËÏÂÂÚÒfl ¢ ‰Ó ·ÂÂÏÂÌÌÓÒÚË. Ç ÔÓ‰‡‚Îfl˛˘ÂÏ ·Óθ¯ËÌÒÚ‚Â ÒÎÛ˜‡Â‚ (ÔËÏÂÌÓ
75%) Ô˘ËÌÓÈ ‡ÌÂÏËË fl‚Îfl˛ÚÒfl ‰ÂÙˈËÚ ÊÂÎÂÁ‡ ËÎË
ÙÓÎË‚ÓÈ ÍËÒÎÓÚ˚ [2]. C.Massot Ë J.Vanderpas ÂÚÓÒÔÂÍÚË‚ÌÓ ËÁÛ˜‡ÎË ˜‡ÒÚÓÚÛ ÊÂÎÂÁÓ‰ÂÙˈËÚÌÓÈ ‡ÌÂÏËË Û
·ÂÂÏÂÌÌ˚ı Ë Ì·ÂÂÏÂÌÌ˚ı ÊÂÌ˘ËÌ ‚ ÅÂθ„ËË [3]. Ç
ÔÂ‚ÓÏ ÚËÏÂÒÚ ·ÂÂÏÂÌÌÓÒÚË ‡ÌÂÏ˲ (ÛÓ‚Â̸ „ÂÏÓ„ÎÓ·Ë̇ <11 „/‰Î) ‚˚fl‚ËÎË Û 4,3% ËÁ 887 ÊÂÌ˘ËÌ, Ô˘ÂÏ Û 35% ËÁ ÌËı ËÏÂÎËÒ¸ ÔËÁ̇ÍË ÊÂÎÂÁÓ‰ÂÙˈËÚ‡
(ÒÌËÊÂÌË ÛÓ‚Ìfl ÙÂËÚË̇ ÏÂÌ 12 ÏÍ„/Î). ç‡ ÔÓÁ‰ÌËı ÒÓ͇ı ·ÂÂÏÂÌÌÓÒÚË ˜‡ÒÚÓÚ‡ ‡ÌÂÏËË Û‚Â΢˂‡Î‡Ò¸. í‡Í, ‚ ÚÂÚ¸ÂÏ ÚËÏÂÒÚ Â ӷ̇ÛÊËÎË Û 31% ËÁ
1313 ÊÂÌ˘ËÌ; Û 75% ËÁ ÌËı ËÏÂÎËÒ¸ ÔËÁ̇ÍË ÊÂÎÂÁÓ‰ÂÙˈËÚ‡. ç‰ÓÒÚ‡ÚÓ˜ÌÓÒÚ¸ ÊÂÎÂÁ‡ Û ·ÂÂÏÂÌÌ˚ı ÊÂÌ˘ËÌ ‚ÒÚ˜‡ÂÚÒfl Á̇˜ËÚÂθÌÓ ˜‡˘Â, ˜ÂÏ ‡ÌÂÏËfl.
ç‡ÔËÏÂ, Q.Liao Ë ÒÓ‡‚Ú. [4] ÔӇ̇ÎËÁËÓ‚‡ÎË ˜‡ÒÚÓÚÛ ËÒÚÓ˘ÂÌËfl Á‡Ô‡ÒÓ‚ ÊÂÎÂÁ‡ Ë ÊÂÎÂÁÓ‰ÂÙˈËÚÌÓÈ ‡ÌÂÏËË ‚ ‡Á΢Ì˚ı „ËÓ̇ı äËÚ‡fl Û 3591 ·ÂÂÏÂÌÌÓÈ
ÊÂÌ˘ËÌ˚. ÑÂÙˈËÚ ÊÂÎÂÁ‡ Ë ‡ÌÂÏËfl ËÏÂÎËÒ¸ Û 42,6 Ë
19,1% Ô‡ˆËÂÌÚÓÍ. àı ˜‡ÒÚÓÚ‡ ·˚· Ò‡ÏÓÈ ‚˚ÒÓÍÓÈ Ì‡
ÔÓÁ‰ÌËı ÒÓ͇ı ·ÂÂÏÂÌÌÓÒÚË. ã‡ÚÂÌÚÌ˚È ‰ÂÙˈËÚ ÊÂÎÂÁ‡ ˜‡˘Â ‚˚fl‚ÎflÎË Û „ÓÓ‰ÒÍËı ÊËÚÂθÌˈ, Ӊ̇ÍÓ
ËÒÍ ‡Á‚ËÚËfl ‡ÌÂÏËË ·˚Î ‚˚¯Â ‚ ÒÂθÒÍÓÈ ÏÂÒÚÌÓÒÚË.
ïÓÚfl ҂‰ÂÌËfl Ó ‚ÎËflÌËË ‡ÌÂÏËË Ì‡ ËÒıÓ‰˚ ·ÂÂÏÂÌÌÓÒÚË ÌÂÓ‰ÌÓÁ̇˜Ì˚, ÚÂÏ Ì ÏÂÌÂÂ, ÏÌÓ„Ë ‡‚ÚÓ˚ ÔÓ·„‡˛Ú, ˜ÚÓ ‡ÌÂÏËfl, ÓÒÓ·ÂÌÌÓ ‚˚‡ÊÂÌ̇fl, Ó͇Á˚‚‡ÂÚ
Ì··„ÓÔËflÚÌÓ ‚ÎËflÌË ̇ Á‰ÓÓ‚¸Â χÚÂË Ë ÔÎÓ‰‡,
˜ÚÓ ÓÔ‰ÂÎflÂÚ ÌÂÓ·ıÓ‰ËÏÓÒÚ¸ ‚ ˝ÙÙÂÍÚË‚ÌÓÈ ÔÓÙË·ÍÚËÍÂ Ë Î˜ÂÌËË ˝ÚÓ„Ó ÒÓÒÚÓflÌËfl.
Диагноз анемии у беременных
Ç ÒÓÓÚ‚ÂÚÒÚ‚ËË Ò ÂÍÓÏẨ‡ˆËflÏË Çéá [5], ÍËÚÂËÂÏ
‰Ë‡„ÌÓÒÚËÍË ‡ÌÂÏËË Û ·ÂÂÏÂÌÌ˚ı ÊÂÌ˘ËÌ fl‚ÎflÂÚÒfl
ÒÌËÊÂÌË ÛÓ‚Ìfl „ÂÏÓ„ÎÓ·Ë̇ ÏÂÌ 11 „/‰Î. èÓ ÏÌÂКЛИНИЧЕСКАЯ ФАРМАКОЛОГИЯ И ТЕРАПИЯ, 2005, 14 (2
)
Ì˲ ‡ÏÂË͇ÌÒÍËı ˝ÍÒÔÂÚÓ‚ (ñÂÌÚ˚ ÔÓ ÍÓÌÚÓβ Ë
ÔÓÙË·ÍÚËÍ Á‡·Ó΂‡ÌËÈ - CDC) [6], ÔË ËÌÚÂÔÂÚ‡ˆËË ÂÁÛθڇÚÓ‚ ÓÔ‰ÂÎÂÌËfl „ÂÏÓ„ÎÓ·Ë̇ ÒΉÛÂÚ Û˜ËÚ˚‚‡Ú¸ ÒÓÍ ·ÂÂÏÂÌÌÓÒÚË. Ç ÌÓÏ ÒÓ‰ÂʇÌËÂ
„ÂÏÓ„ÎÓ·Ë̇ Ë „ÂχÚÓÍËÚÌÓ ˜ËÒÎÓ Ì‡˜Ë̇˛Ú ÒÌËʇڸÒfl ‚ ÔÂ‚ÓÏ ÚËÏÂÒÚ ·ÂÂÏÂÌÌÓÒÚË, ‰ÓÒÚË„‡˛Ú ÏËÌËχθÌ˚ı Á̇˜ÂÌËÈ ‚Ó ‚ÚÓÓÏ ÚËÏÂÒÚÂ, ‡ Á‡ÚÂÏ
ÔÓÒÚÂÔÂÌÌÓ ÔÓ‚˚¯‡˛ÚÒfl. ëÓÓÚ‚ÂÚÒÚ‚ÂÌÌÓ, ‚ ÔÂ‚ÓÏ Ë
ÚÂÚ¸ÂÏ ÚËÏÂÒÚ‡ı ‡ÌÂÏËfl ÏÓÊÂÚ ·˚Ú¸ ‰Ë‡„ÌÓÒÚËÓ‚‡Ì‡ ÔË ÒÌËÊÂÌËË ÛÓ‚Ìfl „ÂÏÓ„ÎÓ·Ë̇ ÏÂÌ 11 „/‰Î, ‡
‚Ó ‚ÚÓÓÏ - ÏÂÌ 10,5 „/‰Î. ÖÒÎË ÊÂÌ˘Ë̇ ‚˚ÍÛË‚‡ÂÚ
ÔÓ 10-20 ÒË„‡ÂÚ ‚ ‰Â̸, ÚÓ Û͇Á‡ÌÌ˚ Á̇˜ÂÌËfl ÒΉÛÂÚ
ÒÍÓÂÍÚËÓ‚‡Ú¸ (+0,3 „/‰Î).
èË Ì‡Î˘ËË ‡ÌÂÏËË Û ·ÂÂÏÂÌÌÓÈ ÌÂÓ·ıÓ‰ËÏÓ ÔÓ‰Ú‚Â‰ËÚ¸ ÊÂÎÂÁÓ‰ÂÙˈËÚ, Ú‡Í Í‡Í ÒÌËÊÂÌË ÛÓ‚Ìfl „ÂÏÓ„ÎÓ·Ë̇ ÏÓÊÂÚ ·˚Ú¸ Ó·ÛÒÎÓ‚ÎÂÌÓ Ë ‰Û„ËÏË
Ù‡ÍÚÓ‡ÏË. ç‡Ë·ÓΠÒÔˆËÙ˘Ì˚Ï ÔÓ͇Á‡ÚÂÎÂÏ fl‚ÎflÂÚÒfl Ò˚‚ÓÓÚÓ˜Ì˚È ÛÓ‚Â̸ ÙÂËÚË̇, ÍÓÚÓ˚È ÓÚ‡Ê‡ÂÚ Ó·˘Ë Á‡Ô‡Ò˚ ÊÂÎÂÁ‡ ‚ Ó„‡ÌËÁÏÂ. ëΉÛÂÚ
Û˜ËÚ˚‚‡Ú¸, ˜ÚÓ Ò˚‚ÓÓÚÓ˜Ì˚È ‡ÔÓÙÂËÚËÌ fl‚ÎflÂÚÒfl
ÓÒÚÓÙ‡ÁÌ˚Ï ·ÂÎÍÓÏ, ÒÓ‰ÂʇÌË ÍÓÚÓÓ„Ó ÔÓ‚˚¯‡ÂÚÒfl
ÔË Î˛·˚ı ËÌÙÂ͈ËÓÌÌ˚ı ËÎË ‚ÓÒÔ‡ÎËÚÂθÌ˚ı ÔÓˆÂÒÒ‡ı. ëÓÓÚ‚ÂÚÒÚ‚ÂÌÌÓ, ‚ Ú‡ÍËı ÒÎÛ˜‡flı ˝ÚÓÚ ÔÓ͇Á‡ÚÂθ
χÎÓ ËÌÙÓχÚË‚ÂÌ. äËÚÂËÂÏ ËÒÚÓ˘ÂÌËfl Á‡Ô‡ÒÓ‚ ÊÂÎÂÁ‡ fl‚ÎflÂÚÒfl ÒÌËÊÂÌË ÛÓ‚Ìfl ÙÂËÚË̇ ÏÂÌ 15
ÏÍ„/Î [5]. ëΉÛÂÚ Û˜ËÚ˚‚‡Ú¸, ˜ÚÓ ÛÏÂ̸¯ÂÌË ÒÓ‰ÂʇÌËfl ÙÂËÚË̇ Ò‡ÏÓ ÔÓ Ò· Ì ÔÓÁ‚ÓÎflÂÚ ÒÛ‰ËÚ¸ Ó
ÙÛÌ͈ËÓ̇θÌÓÏ ‰ÂÙˈËÚ ÊÂÎÂÁ‡. àÌÙÓχÚË‚ÌÓÒÚ¸
ÔÓ͇Á‡ÚÂÎfl ÔË ·ÂÂÏÂÌÌÓÒÚË Ó„‡Ì˘Â̇, Ú‡Í Í‡Í ÓÌ
ÒÌËʇÂÚÒfl ̇ ÔÓÁ‰ÌËı ÒÓ͇ı.
ë ˆÂθ˛ ‚˚fl‚ÎÂÌËfl ÛÏÂÂÌÌÓ„Ó ÊÂÎÂÁÓ‰ÂÙˈËÚ‡ ÏÓÊÂÚ ·˚Ú¸ ËÒÔÓθÁÓ‚‡Ì ˝ËÚÓˆËÚ‡Ì˚È ÔÓÚÓÔÓÙËÌ,
ÍÓÚÓ˚È fl‚ÎflÂÚÒfl Ô‰¯ÂÒÚ‚ÂÌÌËÍÓÏ „Âχ. èÓ‚˚¯ÂÌÌ˚È Â„Ó ÛÓ‚Â̸ ÍÓÂÎËÛÂÚ ÒÓ ÒÌËÊÂÌËÂÏ ÒÓ‰ÂʇÌËfl
ÙÂËÚË̇ ‚ Ò˚‚ÓÓÚÍÂ. é‰Ì‡ÍÓ Û‚Â΢ÂÌË ÍÓ̈ÂÌÚ‡ˆËË ˝ËÚÓˆËÚ‡ÌÓ„Ó ÔÓÚÓÔÓÙË̇ ÏÓÊÂÚ Ì‡·Î˛‰‡Ú¸Òfl ÔË ËÌÙÂ͈ËË, ‚ÓÒÔ‡ÎÂÌËË, ËÌÚÓÍÒË͇ˆËË Ò‚Ë̈ÓÏ
Ë „ÂÏÓÎËÚ˘ÂÒÍÓÈ ‡ÌÂÏËË.
ÑÂÙˈËÚ ÊÂÎÂÁ‡ ÔË‚Ó‰ËÚ Í ÒÌËÊÂÌ˲ Â„Ó Ò˚‚ÓÓ1
èÓÚ·ÌÓÒÚ¸ ‚ ÊÂÎÂÁ (Ï„/ÒÛÚ)
ÚÓ˜ÌÓ„Ó ÒÓ‰ÂʇÌËfl, Û‚Â΢ÂÌ˲ ÛÓ‚Ìfl Ú‡ÌÒÙÂË̇ (Ó·˘ÂÈ ÊÂÎÂÁÓÒ‚flÁ˚‚‡˛˘ÂÈ ÒÔÓÒÓ·ÌÓÒÚË
7
ÍÓ‚Ë) Ë ÛÏÂ̸¯ÂÌ˲ ÒÚÂÔÂÌË Ì‡Ò˚˘ÂÌËfl Ú‡ÌÒÙÂË̇. é‰Ì‡ÍÓ ˝ÚË ÔÓ͇Á‡ÚÂÎË ‚‡ˇ·ÂθÌ˚ Ë
6
̉ÓÒÚ‡ÚÓ˜ÌÓ ËÌÙÓχÚË‚Ì˚ ‚ ‰Ë‡„ÌÓÒÚËÍ ÊÂÎÂèÎÓ‰ Ë
5
Ô·ˆÂÌÚ‡
ÁÓ‰ÂÙˈËÚ‡. ì Ô‡ˆËÂÌÚÓ‚ Ò ·ÓΠ‚˚‡ÊÂÌÌÓÈ ÊÂÎÂÁÓ‰ÂÙˈËÚÌÓÈ ‡ÌÂÏËÂÈ ÒÚÂÔÂ̸ ̇Ò˚˘ÂÌËfl
4
Ú‡ÌÒÙÂË̇ Ó·˚˜ÌÓ ÒÓÒÚ‡‚ÎflÂÚ ÏÂÌ 16%.
ê‡ÌÌËÏ Ë ‰ÓÒÚ‡ÚÓ˜ÌÓ ˜Û‚ÒÚ‚ËÚÂθÌ˚ÏË ÔËÁ̇3
ÍÓÏ Ì‰ÓÒÚ‡ÚÓ˜ÌÓÒÚË ÊÂÎÂÁ‡ fl‚ÎflÂÚÒfl ÔÓ‚˚¯ÂÌËÂ
åÂÌÒÚÛ‡ˆËË
åÂÌÒÚÛ‡ˆËË
ì‚Â΢ÂÌËÂ
˜ËÒ·
ÒÓ‰ÂʇÌËfl Ò˚‚ÓÓÚÓ˜Ì˚ı Ú‡ÌÒÙÂËÌÓ‚˚ı Â2
˝ËÚÓˆËÚÓ‚ ã‡ÍÚ‡ˆËfl
ˆÂÔÚÓÓ‚, ÍÓÚÓÓ Ì Á‡‚ËÒËÚ ÓÚ Ì‡Î˘Ëfl ËÌÙÂÍ1
ˆËË ËÎË ‚ÓÒÔ‡ÎÂÌËfl, ‡ Ú‡ÍÊ ‚ÓÁ‡ÒÚ‡, ÔÓ· ËÎË
èÓÚÂË ÊÂÎÂÁ‡
·ÂÂÏÂÌÌÓÒÚË [7]. é‰Ì‡ÍÓ Ëı ÛÓ‚Â̸ ÏÓÊÂÚ ÔÓ‚˚0
èÓÒÎÂÓ‰Ó‚˚È
ÒËÚ¸Òfl ÔË Û‚Â΢ÂÌËË Ó·‡ÁÓ‚‡ÌËfl ˝ËÚÓˆËÚÓ‚,
èÂ‚˚È
ÇÚÓÓÈ
íÂÚËÈ
ÔÂËÓ‰
̇ÔËÏÂ, ÔË „ÂÏÓÎËÚ˘ÂÒÍÓÈ ‡ÌÂÏËË. äÓÏ ÚÓíËÏÂÒÚ˚ ·ÂÂÏÂÌÌÓÒÚË
„Ó, ÂÁÛθڇÚ˚ ÚÂÒÚ‡ Á‡‚ËÒflÚ ÓÚ ËÒÔÓθÁÛÂÏÓ„Ó ÏÂÚÓ‰‡ ‡Ì‡ÎËÁ‡ (˜‡˘Â ‚ÒÂ„Ó ÔËÏÂÌfl˛Ú ELISA).
èË ‡Ì‡ÎËÁ ҇ÏËı ˝ËÚÓˆËÚÓ‚ ÔËÁ͇̇ÏË Рис. 1. Диниамика потребности в железе во время беременности
ÊÂÎÂÁÓ‰ÂÙˈËÚ‡ fl‚Îfl˛ÚÒfl ÒÌËÊÂÌË Ò‰ÌÂ„Ó Ëı
Ó·˙Âχ Ë Ò‰ÌÂ„Ó ÒÓ‰ÂʇÌËfl „ÂÏÓ„ÎÓ·Ë̇. ìÏÂ̸¯Â- ÚËÏÂÒÚ‡ı ·ÂÂÏÂÌÌÓÒÚË ÒÓÒÚ‡‚ÎflÂÚ 4-6 Ï„, ‡ ‚ ÔÓÒΉÌË ÔÂ‚Ó„Ó ÔÓ͇Á‡ÚÂÎfl ÓÚϘ‡ÂÚÒfl ̇ ÔÓÁ‰ÌËı ˝Ú‡Ô‡ı ÌË 6-8 ̉Âθ ‰ÓÒÚË„‡ÂÚ 10 Ï„. ÖÒÎË ÊÂÌ˘Ë̇ ÔËÚ‡ÂÚÒfl
‡Á‚ËÚËfl ‡ÌÂÏËË. 燉ÂÊÌ˚Ï ÏÂÚÓ‰ÓÏ ‰Ë‡„ÌÓÒÚËÍË Ò˜Ë- ÔÓ‰ÛÍÚ‡ÏË, ÒÓ‰Âʇ˘ËÏË ·Óθ¯Ó ÍÓ΢ÂÒÚ‚Ó ÊÂÎÂÁ‡
Ú‡˛Ú Ú‡ÍÊ ÓÍ‡ÒÍÛ ÍÓÒÚÌÓ„Ó ÏÓÁ„‡ ̇ ÊÂÎÂÁ‡, ıÓÚfl ÓÌ ‚ ·ËÓ‰ÓÒÚÛÔÌÓÈ ÙÓÏ (ÏflÒÓ, ÔÚˈ‡, ˚·‡), ‡ Ú‡ÍÊ ‡ÒÍÓ·ËÌÓ‚ÓÈ ÍËÒÎÓÚ˚, ÚÓ ‚ ˆÂÎÓÏ ‚Ò‡Ò˚‚‡ÌË ÊÂÎÂÁ‡ ÒÓÌ ÏÓÊÂÚ ·˚Ú¸ ËÒÔÓθÁÓ‚‡Ì ‰Îfl ÒÍËÌËÌ„‡.
ê‡ÒÔÓÒÚ‡ÌÂÌÌ˚Ï ÔÓ‰ıÓ‰ÓÏ Í ‰Ë‡„ÌÓÒÚËÍ ÊÂÎÂÁÓ- ÒÚ‡‚ÎflÂÚ 3-4 Ï„/ÒÛÚ. í‡ÍËÏ Ó·‡ÁÓÏ, ‰‡Ê ‚ ÎÛ˜¯ÂÏ
‰ÂÙˈËÚÌÓÈ ‡ÌÂÏËÂÈ fl‚ÎflÂÚÒfl ËÁÛ˜ÂÌË ‰Ë̇ÏËÍË ÒÎÛ˜‡Â, Ú.Â. ÔË ‡‰ÂÍ‚‡ÚÌÓÏ ÔËÚ‡ÌËË, ·ÂÂÏÂÌ̇fl ÊÂÌÛÓ‚Ìfl „ÂÏÓ„ÎÓ·Ë̇ ËÎË „ÂχÚÓÍËÚÌÓ„Ó ˜ËÒ· ÔË ÔÂ- ˘Ë̇ ÔÓÎÛ˜‡ÂÚ ˜ÛÚ¸ ÏÂ̸¯Â ÊÂÎÂÁ‡, ˜ÂÏ ÂÈ Ú·ÛÂÚÒfl.
é˜Â‚ˉÌÓ, ˜ÚÓ ‚ ˝ÚÓÈ ÒËÚÛ‡ˆËË ·‡Î‡ÌÒ ÊÂÎÂÁ‡ ‚ Ó„‡Ó‡Î¸ÌÓÏ ÔËÏÂÌÂÌËË ÔÂÔ‡‡ÚÓ‚ ÊÂÎÂÁ‡. èËÁ̇ÍÓÏ
ÊÂÎÂÁÓ‰ÂÙˈËÚ‡ ÏÓÊÂÚ ÒÎÛÊËÚ¸ Û‚Â΢ÂÌË ÛÓ‚Ìfl „Â- ÌËÁÏ ÏÓÊÂÚ ÔÓ‰‰ÂÊË‚‡Ú¸Òfl ÚÓθÍÓ ÔË Ì‡Î˘ËË ‡‰ÂÍÏÓ„ÎÓ·Ë̇ ÔÓ Í‡ÈÌÂÈ ÏÂ ̇ 1 „/‰Î ˜ÂÂÁ 1-2 ÏÂÒflˆ‡ ‚‡ÚÌ˚ı Á‡Ô‡ÒÓ‚ ÊÂÎÂÁ‡ ‰Ó ·ÂÂÏÂÌÌÓÒÚË. ÖÒÎË
·ÂÂÏÂÌ̇fl ÊÂÌ˘Ë̇ ÔËÚ‡ÂÚÒfl ÌÓχθÌÓ, ÚÓ ˝ÚË Á‡Ô‡ÔÓÒΠ̇˜‡Î‡ ΘÂÌËfl.
Ò˚ ‰ÓÎÊÌ˚ ÒÓÒÚ‡‚ÎflÚ¸ ÔÓ Í‡ÈÌÂÈ ÏÂ 300 Ï„, ÌÓ ‚
ÔÓÚË‚ÌÓÏ ÒÎÛ˜‡Â ÓÌË ‰ÓÎÊÌ˚ ·˚Ú¸ ‚˚¯Â. èÓ ‰‡ÌÌ˚Ï
Обмен железа во время беременности
Ç ÔÂ‚ÓÏ ÚËÏÂÒÚ ·ÂÂÏÂÌÌÓÒÚË ÔÓÚ·ÌÓÒÚ¸ ‚ ÊÂÎÂÁ ËÒÒΉӂ‡ÌËfl, ÍÓÚÓÓ ÔÓ‚Ó‰ËÎÓÒ¸ ‚ ëòÄ [9], ωˇÒÌËʇÂÚÒfl Á‡ Ò˜ÂÚ ÔÂÍ‡˘ÂÌËfl Â„Ó ÔÓÚÂË ‚Ó ‚ÂÏfl ̇ ‡Ò˜ÂÚÌ˚ı Á‡Ô‡ÒÓ‚ ÊÂÎÂÁ‡ Û ÊÂÌ˘ËÌ ÒÓÒÚ‡‚Ë· 300
ÏÂÌÒÚÛ‡ˆËÈ. Ç ˝ÚÓÚ ÔÂËÓ‰ ÊÂÌ˘Ë̇ ÚÂflÂÚ ÏËÌËχθ- Ï„, ‡ Û 20% ÓÌË Ù‡ÍÚ˘ÂÒÍË ÓÚÒÛÚÒÚ‚Ó‚‡ÎË. Ç ò‚ˆËË
ÌÓ ÍÓ΢ÂÒÚ‚Ó ÊÂÎÂÁ‡ - ÓÍÓÎÓ 0,8 Ï„/ÒÛÚ - ˜ÂÂÁ ÊÂÎÛ- ωˇ̇ Á‡Ô‡ÒÓ‚ ÊÂÎÂÁ‡ Û ÊÂÌ˘ËÌ ÒÓÒÚ‡‚Ë· ‚ÒÂ„Ó 150
‰Ó˜ÌÓ-Í˯˜Ì˚È Ú‡ÍÚ, ÍÓÊÛ Ë Ò ÏÓ˜ÓÈ (Ú‡Í Ï„, ‡ Û ‰Â‚Û¯ÂÍ ÒÚ‡¯Â 15 ÎÂÚ - 70 Ï„ [10]. ã˯¸ Û 20%
̇Á˚‚‡ÂÏ˚ “·‡Á‡Î¸Ì˚” ÔÓÚÂË). é‰Ì‡ÍÓ ‚Ó ‚ÚÓÓÏ Ó·ÒΉӂ‡ÌÌ˚ı ÓÌË Ô‚˚¯‡ÎË 250 Ï„. Ç ˝ÚËı ÛÒÎÓ‚Ëflı
ÚËÏÂÒÚ ÔÓÚ·ÌÓÒÚ¸ ‚ ÊÂÎÂÁ ̇˜Ë̇ÂÚÒfl Û‚Â΢Ë- ÌÂۉ˂ËÚÂθÌÓ, ˜ÚÓ ‚Ó ‚ÂÏfl ·ÂÂÏÂÌÌÓÒÚË ÛÒÛ„Û·ÎflÂÚÒfl
‚‡Ú¸Òfl Ë ÔÓ‰ÓÎʇÂÚ ‡ÒÚË ‰Ó ÍÓ̈‡ ·ÂÂÏÂÌÌÓÒÚË (ËÒ. ËÎË ‡Á‚Ë‚‡ÂÚÒfl ‰ÂÙˈËÚ ÊÂÎÂÁ‡, ˜ÚÓ ÔË‚Ó‰ËÚ Í ÔÓfl‚1) [8]. ì‚Â΢ÂÌË ÔÓÚ·ÎÂÌËfl ÍËÒÎÓÓ‰‡ χÚÂ¸˛ Ë ÎÂÌ˲ ‡ÌÂÏËË.
ÔÎÓ‰ÓÏ ÒÓÔÓ‚Óʉ‡ÂÚÒfl Á̇˜ËÚÂθÌ˚Ï ÔÓ‚˚¯ÂÌËÂÏ
Ó·˙Âχ ˆËÍÛÎËÛ˛˘ÂÈ Ô·ÁÏ˚ (ÔËÏÂÌÓ Ì‡ 50%) Ë Неблагоприятные эффекты анемии
χÒÒ˚ ˝ËÚÓˆËÚÓ‚ (̇ 35%). óÚÓ·˚ Ó·ÂÒÔ˜ËÚ¸ ÔÓ‰Ó·- ÑÎfl ÌÓχθÌÓ„Ó ‡Á‚ËÚËfl Ó„‡ÌÓ‚ ÔÎÓ‰‡ Ë ÌÓ‚ÓÓÊÌ˚ ËÁÏÂÌÂÌËfl, Ó„‡ÌËÁÏÛ ÊÂÌ˘ËÌ˚ Ú·ÛÂÚÒfl ÔËÏÂ- ‰ÂÌÌÓ„Ó ÌÂÓ·ıÓ‰ËÏÓ ‰ÓÒÚ‡ÚÓ˜ÌÓ ÔÓÒÚÛÔÎÂÌË ÊÂÎÂÁ‡
ÌÓ 450 Ï„ ÊÂÎÂÁ‡. Ç ‰‡Î¸ÌÂȯÂÏ ÓÒÚ ÔÓÚ·ÌÓÒÚË ‚ [11]. ÅÓθ¯‡fl ˜‡ÒÚ¸ Â„Ó ‚ıÓ‰ËÚ ‚ ÒÓÒÚ‡‚ „ÂÏÓ„ÎÓ·Ë̇, ‡
ÊÂÎÂÁ ÔÓËÒıÓ‰ËÚ ÔÓÔÓˆËÓ̇θÌÓ Û‚Â΢ÂÌ˲ χÒ- ÏÂ̸¯‡fl ˜‡ÒÚ¸ ÔÓÒÚÛÔ‡ÂÚ ‚ ‰ÂÔÓ (ÙÂËÚËÌ) ËÎË
Ò˚ ÔÎÓ‰‡. ëÓ‰ÂʇÌË ÊÂÎÂÁ‡ ‚ Ó„‡ÌËÁÏ ÔÎÓ‰‡ χÒÒÓÈ ËÒÔÓθÁÛ˛ÚÒfl ‰Îfl ÒËÌÚÂÁ‡ fl‰‡ ‡ÍÚË‚Ì˚ı ·ÂÎÍÓ‚, ‚ ˜‡ÒÚÚ· >3 Í„ ÒÓÒÚ‡‚ÎflÂÚ ÓÍÓÎÓ 270 Ï„, ‡ ‚ Ô·ˆÂÌÚ - 90 Ï„. ÌÓÒÚË ÏËÓ„ÎÓ·Ë̇ Ë ˆËÚÓıÓÏÓ‚. èË ‰ÂÙˈËÚ ÊÂÎÂÁ‡
äÓÏ ÚÓ„Ó, ÊÂÌ˘Ë̇ ÚÂflÂÚ ÓÍÓÎÓ 150 Ï„ ÊÂÎÂÁ‡ Ò ÍÓ- ÓÌÓ ÔÂËÏÛ˘ÂÒÚ‚ÂÌÌÓ ‡ÒıÓ‰ÛÂÚÒfl ̇ ÒËÌÚÂÁ „ÂÏÓ„ÎÓ·Ë‚¸˛ ‚Ó ‚ÂÏfl Ó‰Ó‚. í‡ÍËÏ Ó·‡ÁÓÏ, ‚ ˆÂÎÓÏ ÊÂÌ˘ËÌ ̇, ‚ ÚÓ ‚ÂÏfl Í‡Í ÒÍÂÎÂÚÌ˚ Ï˚¯ˆ˚, ÒÂ‰ˆÂ Ë „ÓÎÓÁ‡ ‚ÂÏfl ·ÂÂÏÂÌÌÓÒÚË Ë Ó‰Ó‚ Ú·ÛÂÚÒfl ·ÓΠ1000 Ï„ ‚ÌÓÈ ÏÓÁ„ ËÒÔ˚Ú˚‚‡˛Ú ‰ÂÙˈËÚ ˝ÚÓ„Ó ˝ÎÂÏÂÌÚ‡ ¢ ‰Ó
ÊÂÎÂÁ‡.
ÔÓfl‚ÎÂÌËfl ÔËÁ̇ÍÓ‚ ÊÂÎÂÁÓ‰ÂÙˈËÚÌÓÈ ‡ÌÂÏËË.
ëÛÚӘ̇fl ÔÓÚ·ÌÓÒÚ¸ ‚ ÊÂÎÂÁ ‚Ó ‚ÚÓÓÏ-ÚÂÚ¸ÂÏ í‡ÌÒÔÓÚ ÊÂÎÂÁ‡ ÓÚ Ï‡ÚÂË Í ÔÎÓ‰Û ÔÓËÒıÓ‰ËÚ ‚
2
КЛИНИЧЕСКАЯ ФАРМАКОЛОГИЯ И ТЕРАПИЯ, 2005, 14 (2)
ÓÒÌÓ‚ÌÓÏ ÔÓÒΠ30-È Ì‰ÂÎË ·ÂÂÏÂÌÌÓÒÚË, ÍÓ„‰‡ „Ó
‚Ò‡Ò˚‚‡ÌË ‚ Ó„‡ÌËÁÏ ÊÂÌ˘ËÌ˚ ‰ÓÒÚË„‡ÂÚ ÔË͇.
í‡ÌÒÔÓÚ ÓÒÛ˘ÂÒÚ‚ÎflÂÚÒfl Ò˚‚ÓÓÚÓ˜Ì˚Ï Ú‡ÌÒÙÂËÌÓÏ, ÍÓÚÓ˚È Ò‚flÁ˚‚‡ÂÚÒfl Ò Ú‡ÌÒÙÂËÌÓ‚˚ÏË ˆÂÔÚÓ‡ÏË Ì‡ ÔÓ‚ÂıÌÓÒÚË Ô·ˆÂÌÚ˚ Ë ÔÓ‰‚Â„‡ÂÚÒfl
˝Ì‰ÓˆËÚÓÁÛ. èÓÒΠ‚˚Ò‚Ó·ÓʉÂÌËfl ÊÂÎÂÁ‡ ‡ÔÓÚ‡ÌÒÙÂËÌ ‚ÓÁ‚‡˘‡ÂÚÒfl ‚ χÚÂËÌÒÍËÈ ÍÓ‚ÓÚÓÍ, ‡ Ò‚Ó·Ó‰ÌÓ ÊÂÎÂÁÓ Ò‚flÁ˚‚‡ÂÚÒfl Ò Ú‡ÌÒÙÂËÌÓÏ ‚ ÍÎÂÚ͇ı
Ô·ˆÂÌÚ˚, ‡ Á‡ÚÂÏ ÔÓÒÚÛÔ‡ÂÚ ‚ ÍÓ‚¸ ÔÎÓ‰‡. èË Ì‰ÓÒÚ‡ÚÓ˜ÌÓÏ ÒÓ‰ÂʇÌËË ÊÂÎÂÁ‡ ‚ ÍÓ‚Ë ‚ Ô·ˆÂÌÚ ۂÂ΢˂‡ÂÚÒfl ˜ËÒÎÓ Ú‡ÌÒÙÂËÌÓ‚˚ı ˆÂÔÚÓÓ‚, ˜ÚÓ
Ó·ÂÒÔ˜˂‡ÂÚ ÛÒËÎÂÌÌ˚È Á‡ı‚‡Ú ÊÂÎÂÁ‡. Ç Ò‚Ó˛ Ó˜Â‰¸,
ËÁ·˚ÚÓ˜ÌÓ ÔÓÒÚÛÔÎÂÌË ÊÂÎÂÁ‡ ÏÓÊÂÚ ·˚Ú¸ Ô‰ÓÚ‚‡˘ÂÌÓ ÔÛÚÂÏ ÒËÌÚÂÁ‡ ÙÂËÚË̇ ‚ Ô·ˆÂÌÚÂ. èË Ì‡Î˘ËË ÊÂÎÂÁÓ‰ÂÙˈËÚ‡ Û ÊÂÌ˘ËÌ˚ ÙÛÌ͈ËÓÌËÓ‚‡ÌËÂ
˝ÚÓÈ ÒËÒÚÂÏ˚ ÏÓÊÂÚ Ì‡Û¯ËÚ¸Òfl.
ÄÌÂÏËfl β·ÓÈ ÔËÓ‰˚ Ó͇Á˚‚‡ÂÚ ÌÂÊ·ÚÂθÌÓÂ
‰ÂÈÒÚ‚Ë ̇ ÔÎÓ‰ Ë fl‚ÎflÂÚÒfl Ó‰ÌÓÈ ËÁ Ô˘ËÌ Á‡‰ÂÊÍË
‚ÌÛÚËÛÚÓ·ÌÓ„Ó ‡Á‚ËÚËfl, ‡ÒÒÓˆËËÛ˛˘ÂÈÒfl Ò ÔÓ‚˚¯ÂÌÌÓÈ Á‡·Ó΂‡ÂÏÓÒÚ¸˛ Ë ÒÏÂÚÌÓÒÚ¸˛. ÅÓΠÚÓ„Ó,
‚˚Ò͇Á‡Ì‡ „ËÔÓÚÂÁ‡ Ó ÚÓÏ, ˜ÚÓ Á‡‰ÂÊ͇ ‚ÌÛÚËÛÚÓ·ÌÓ„Ó ‡Á‚ËÚËfl fl‚ÎflÂÚÒfl Ù‡ÍÚÓÓÏ ËÒ͇ ‡Á‚ËÚËfl ‡ÚÂˇθÌÓÈ „ËÔÂÚÓÌËË, ˯ÂÏ˘ÂÒÍÓÈ ·ÓÎÂÁÌË ÒÂ‰ˆ‡ Ë
ıÓÌ˘ÂÒÍÓÈ Ó·ÒÚÛÍÚË‚ÌÓÈ ·ÓÎÂÁÌË Î„ÍËı ‚ ÁÂÎÓÏ
‚ÓÁ‡ÒÚ („ËÔÓÚÂÁ‡ ŇÍÂ‡) [12,13]. Ç ÒÓÓÚ‚ÂÚÒÚ‚ËË Ò
˝ÚÓÈ „ËÔÓÚÂÁÓÈ, ÒÚÛÍÚÛ‡ Ë ÙÛÌ͈ËË ‡ÁÌ˚ı Ó„‡ÌÓ‚
ÓÔ‰ÂÎÂÌÌ˚Ï Ó·‡ÁÓÏ ÔÓ„‡ÏÏËÛ˛ÚÒfl ‚ ÔÂËÓ‰ ˝Ï·ËÓ̇θÌÓ„Ó ‡Á‚ËÚËfl [14]. èӉӷ̇fl ÔÓ„‡Ïχ ÓÔ‰ÂÎflÂÚ Ëı ÙËÁËÓÎӄ˘ÂÒÍËÂ Ë ÏÂÚ‡·Ó΢ÂÒÍË ÓÚ‚ÂÚÌ˚Â
‡͈ËË ‚ ÁÂÎÓÏ ‚ÓÁ‡ÒÚÂ. ç‡Û¯ÂÌË ÔÓÒÚÛÔÎÂÌËfl ÔËÚ‡ÚÂθÌ˚ı ‚¢ÂÒÚ‚ ‚Ó ‚ÂÏfl ·ÂÂÏÂÌÌÓÒÚË ‚˚Á˚‚‡ÂÚ
‡‰‡ÔÚË‚Ì˚È ÓÚ‚ÂÚ ÔÎÓ‰‡ (‚ ˜‡ÒÚÌÓÒÚË „ÓÏÓ̇θÌ˚È),
ÍÓÚÓ˚È ÏÓÊÂÚ ·˚Ú¸ Ô˘ËÌÓÈ “ÏÂÚ‡·Ó΢ÂÒÍÓ„Ó ÍÓÌÙÎËÍÚ‡” ÔË ‚ÓÒÒÚ‡ÌÓ‚ÎÂÌËË ÌÓχθÌÓ„Ó ÔËÚ‡ÌËfl
ÔÓÒΠÓ‰Ó‚. ùÚÓÚ ÍÓÌÙÎËÍÚ Ô‰‡ÒÔÓ·„‡ÂÚ Í Ì‡Û¯ÂÌ˲ ‡Á΢Ì˚ı ÙËÁËÓÎӄ˘ÂÒÍËı ÙÛÌ͈ËÈ Ë ‡Á‚ËÚ˲
fl‰‡ Á‡·Ó΂‡ÌËÈ.
êÂÁÛθڇÚ˚ ˝ÔˉÂÏËÓÎӄ˘ÂÒÍËı ËÒÒΉӂ‡ÌËÈ ÔÓ‰Ú‚Âʉ‡˛Ú ˝ÚÛ „ËÔÓÚÂÁÛ. ç‡ÔËÏÂ, ‚ ÇÂÎËÍÓ·ËÚ‡ÌËË
·˚· ÔÓÒÎÂÊÂ̇ ÒÛ‰¸·‡ 16000 ÏÛʘËÌ Ë ÊÂÌ˘ËÌ, Ӊ˂¯ËıÒfl ‚ 1911-1930 „„. [15]. ì‚Â΢ÂÌË χÒÒ˚ ÌÓ‚ÓÓʉÂÌÌ˚ı ‰ÂÚÂÈ (ÓÚ <2500 ‰Ó >4310 „) ‡ÒÒÓˆËËÓ‚‡ÎÓÒ¸
ÒÓ Á̇˜ËÚÂθÌ˚Ï ÒÌËÊÂÌËÂÏ Ëı ÒÏÂÚÌÓÒÚË ÓÚ ÍÓÓ̇ÌÓÈ ·ÓÎÂÁÌË ÒÂ‰ˆ‡ ‚ ÓÚ‰‡ÎÂÌÌÓÏ ÔÂËÓ‰Â. ëıÓ‰Ì˚Â
‰‡ÌÌ˚ ·˚ÎË ÔÓÎÛ˜ÂÌ˚ ÔË ‡Ì‡ÎËÁ ˜‡ÒÚÓÚ˚ ‡ÚÂˇθÌÓÈ „ËÔÂÚÓÌËË Ë Ò‡ı‡ÌÓ„Ó ‰Ë‡·ÂÚ‡. ó‡ÒÚÓÚ‡ Ò‡ı‡ÌÓ„Ó ‰Ë‡·ÂÚ‡ ÚËÔ‡ 2 Ë Ì‡Û¯ÂÌËfl ÚÓÎÂ‡ÌÚÌÓÒÚË Í „βÍÓÁÂ
Û ÏÛʘËÌ, ÍÓÚÓ˚ ‚ÂÒËÎË ÔË ÓʉÂÌËË ÏÂÌ 2500 „,
·˚· ‚ 3 ‡Á‡ ‚˚¯Â, ˜ÂÏ Û ÏÛʘËÌ, ‚ÂÒ ÍÓÚÓ˚ı ÔË
ÓʉÂÌËË ÒÓÒÚ‡‚ÎflÎ ·ÓΠ4310 „ (14 Ë 40% ÒÓÓÚ‚ÂÚÒÚ‚ÂÌÌÓ [16].
åÂı‡ÌËÁÏ˚ ÔÓ‰Ó·Ì˚ı Ò‚flÁÂÈ ‰Ó ÍÓ̈‡ Ì flÒÌ˚.
Ç˚Ò͇Á˚‚‡ÎÓÒ¸ Ô‰ÔÓÎÓÊÂÌËÂ Ó ÚÓÏ, ˜ÚÓ ÌËÁ͇fl χÒÒ‡
Ú· ÌÓ‚ÓÓʉÂÌÌÓ„Ó ÔÓ‚˚¯‡ÂÚ ‚ÂÓflÚÌÓÒÚ¸ ÔÓÒÎÂ‰Û˛˘Â„Ó Û‚Â΢ÂÌËfl ÛÓ‚ÌÂÈ ıÓÎÂÒÚÂË̇ ‚ ÍÓ‚Ë, Ӊ̇ÍÓ
˝Ú‡ Ò‚flÁ¸ Ì ·˚· ÔÓ‰Ú‚ÂʉÂ̇ ÔË ÏÂÚ‡-‡Ì‡ÎËÁ 79 ËÒКЛИНИЧЕСКАЯ ФАРМАКОЛОГИЯ И ТЕРАПИЯ, 2005, 14 (2)
ÒΉӂ‡ÌËÈ ‚ ˆÂÎÓÏ Û 74122 Ô‡ˆËÂÌÚÓ‚ [17]. éÔ‰ÂÎÂÌÌÓ Á̇˜ÂÌË ÏÓ„ÛÚ ËÏÂÚ¸ ÒÚÓÈÍË ËÁÏÂÌÂÌËfl ÒËÒÚÂÏ˚
„ËÔÓڇ·ÏÛÒ-„ËÔÓÙËÁ, ÏÂı‡ÌËÁÏÓ‚, „ÛÎËÛ˛˘Ë ÒÂÍÂˆË˛ ËÌÒÛÎË̇ Ë ˜Û‚ÒÚ‚ËÚÂθÌÓÒÚ¸ Í ÌÂÏÛ, Ë ÒÓÒÛ‰ËÒÚÓÈ ‡ÍÚË‚ÌÓÒÚË [18]. S.Mahajan Ë ÒÓ‡‚Ú. [19] ÔÓ͇Á‡ÎË,
˜ÚÓ ‡ÌÂÏËfl Û ·ÂÂÏÂÌÌ˚ı ÒÓÔÓ‚Óʉ‡ÂÚÒfl ·ÓΠ‚˚‡ÊÂÌÌ˚Ï Û‚Â΢ÂÌËÂÏ ÛÓ‚ÌÂÈ „ÓÏÓÌÓ‚ ÓÒÚ‡, ÔÓ·ÍÚË̇ Ë ËÌÒÛÎËÌÓÔÓ‰Ó·ÌÓ„Ó Ù‡ÍÚÓ‡ ÓÒÚ‡-1 ‚ ÍÓ‚Ë
ÔÛÔÓ‚ËÌ˚. èÓ ÏÌÂÌ˲ L.Allen [20], ‡ÌÂÏËfl („ËÔÓÍÒËfl)
Ë ‰ÂÙˈËÚ ÊÂÎÂÁ‡ (ÒÓÔÓ‚Óʉ‡˛˘ËÈÒfl Û‚Â΢ÂÌËÂÏ
Ò˚‚ÓÓÚÓ˜ÌÓÈ ÍÓ̈ÂÌÚ‡ˆËË ÌÓ‡‰Â̇ÎË̇) ‚˚Á˚‚‡˛Ú
ÒÚÂÒÒÓÌÛ˛ Â‡ÍˆË˛ Û Ï‡ÚÂË Ë ÔÎÓ‰‡, ÍÓÚÓ‡fl ÒÚËÏÛÎËÛÂÚ ÒËÌÚÂÁ ÍÓÚËÍÓÚÓÔËÌ-ËÎËÁËÌ„ „ÓÏÓ̇. èÓ‚˚¯ÂÌË ÛÓ‚Ìfl ÔÓÒΉÌÂ„Ó fl‚ÎflÂÚÒfl ÓÒÌÓ‚Ì˚Ï Ù‡ÍÚÓÓÏ
ËÒ͇ ÔÂʉ‚ÂÏÂÌÌ˚ı Ó‰Ó‚, ‡ÚÂˇθÌÓÈ „ËÔÂÚÓÌËË Ë ˝Í·ÏÔÒËË. äÓÏ ÚÓ„Ó, ˝ÚÓÚ „ÓÏÓÌ ÒÚËÏÛÎËÛÂÚ
ÔÓ‰ÛÍˆË˛ ÍÓÚËÁÓ·, ÍÓÚÓ˚È ÏÓÊÂÚ Á‡Ï‰ÎËÚ¸ ÓÒÚ
ÔÎÓ‰‡. ÑÂÙˈËÚ ÊÂÎÂÁ‡ ÏÓÊÂÚ ·˚Ú¸ Ô˘ËÌÓÈ ÓÍËÒÎËÚÂθÌÓ„Ó ÒÚÂÒ‡, ‡ Ú‡ÍÊ ÔÓ‚˚¯‡ÂÚ ËÒÍ ËÌÙÂ͈ËÈ, ÍÓÚÓ˚ ÌÂ‰ÍÓ ÒÓÔÓ‚Óʉ‡˛ÚÒfl ÔÂʉ‚ÂÏÂÌÌ˚ÏË
Ó‰‡ÏË.
Влияние анемии на исходы беременности
èÓ ‰‡ÌÌ˚Ï Çéá [5], ‡ÌÂÏËfl Ë ‰ÂÙˈËÚ ÊÂÎÂÁ‡ Û ·ÂÂÏÂÌÌ˚ı ‡ÒÒÓˆËËÛ˛ÚÒfl Ò ÔÓ‚˚¯ÂÌËÂÏ Ï‡ÚÂËÌÒÍÓÈ
ÒÏÂÚÌÓÒÚË, ÔÂË̇ڇθÌÓÈ ÒÏÂÚÌÓÒÚË Ë Û‚Â΢ÂÌËÂÏ
˜‡ÒÚÓÚ˚ ÔÂʉ‚ÂÏÂÌÌ˚ı Ó‰Ó‚. B.Brabin Ë ÒÓ‡‚Ú. [21]
ÔÓ‚ÂÎË ÏÂÚ‡-‡Ì‡ÎËÁ ËÒÒΉӂ‡ÌËÈ, ‚ ÍÓÚÓ˚ı ËÁÛ˜‡ÎÓÒ¸ ‚ÎËflÌË ‡ÌÂÏËË ‚Ó ‚ÂÏfl ·ÂÂÏÂÌÌÓÒÚË Ì‡ χÚÂËÌÒÍÛ˛ ÒÏÂÚÌÓÒÚ¸. éÚÌÓÒËÚÂθÌ˚È ËÒÍ ÒÏÂÚË ÔË
ÛÏÂÂÌÌÓÈ ‡ÌÂÏËË („ÂÏÓ„ÎÓ·ËÌ 4-8 „/‰Î) ÒÓÒÚ‡‚ËÎ 1,35
(95% ‰Ó‚ÂËÚÂθÌ˚È ËÌÚÂ‚‡Î 0,92-2,00), ‡ ÔË ÚflÊÂÎÓÈ
‡ÌÂÏËË (<4,7 „/‰Î) - 3,51 (95% ‰Ó‚ÂËÚÂθÌ˚È ËÌÚÂ‚‡Î
2,05-6,00). ëΉÛÂÚ ÓÚÏÂÚËÚ¸, ˜ÚÓ Ò‚flÁ¸ ÏÂÊ‰Û ‡ÌÂÏËÂÈ Ë
χÚÂËÌÒÍÓÈ ÒÏÂÚÌÓÒÚ¸˛ ‚ ÔÓÒÔÂÍÚË‚Ì˚ı ËÒÒΉӂ‡ÌËflı Ì ‰Ó͇Á‡Ì‡, ‡ ̇ ÂÁÛθڇÚ˚ Ëϲ˘ËıÒfl ËÒÒΉӂ‡ÌËÈ ÏÓ„ÎË Ó͇Á‡Ú¸ ‚ÎËflÌË ‡Á΢Ì˚ هÍÚÓ˚.
ç‡ÔËÏÂ, ‚ ÍÛÔÌÓÏ Ë̉ÓÌÂÁËÈÒÍÓÏ ËÒÒΉӂ‡ÌËË
ÒÏÂÚÌÓÒÚ¸ ·ÂÂÏÂÌÌ˚ı ÊÂÌ˘ËÌ, ÒÚ‡‰‡‚¯Ëı Ë Ì ÒÚ‡‰‡‚¯Ëı ‡ÌÂÏËÂÈ („ÂÏÓ„ÎÓ·ËÌ <10 „/‰Î) ÒÓÒÚ‡‚Ë· 70,0 Ë
19,7 ̇ 10000 Ó‰Ó‚ ÒÓÓÚ‚ÂÚÒÚ‚ÂÌÌÓ [22]. é‰Ì‡ÍÓ ÔÓ
ÏÌÂÌ˲ ‡‚ÚÓÓ‚, Û‚Â΢ÂÌË ÒÏÂÚÌÓÒÚË ÏÓ„ÎÓ ·˚Ú¸ ÂÁÛθڇÚÓÏ ·ÓΠ‚˚‡ÊÂÌÌÓ„Ó ÍÓ‚ÓÚ˜ÂÌËfl ËÎË ÔÓÁ‰ÌÂÈ „ÓÒÔËÚ‡ÎËÁ‡ˆËË, ‡ Ì ҇ÏÓÈ ‡ÌÂÏËË.
K.Rasmussen [23] Ôӂ· ÒËÒÚÂχÚËÁËÓ‚‡ÌÌ˚È 54
Ó·ÁÓ ËÒÒΉӂ‡ÌËÈ, ‚ ÍÓÚÓ˚ı ËÁÛ˜‡Î‡Ò¸ Ò‚flÁ¸ ÏÂʉÛ
ÛÓ‚ÌÂÏ „ÂÏÓ„ÎÓ·Ë̇ ËÎË „ÂχÚÓÍËÚÓÏ Ë ËÒıÓ‰‡ÏË ·ÂÂÏÂÌÌÓÒÚË. Ç 26 ËÁ 44 ËÒÒΉӂ‡ÌËÈ ‡ÌÂÏËfl ËÎË ÌËÁ͇fl ÍÓ̈ÂÌÚ‡ˆËfl ÙÂËÚË̇ ‡ÒÒÓˆËËÓ‚‡ÎËÒ¸ Ò
Û‚Â΢ÂÌËÂÏ ˜‡ÒÚÓÚ˚ ÓʉÂÌËfl ‰ÂÚÂÈ Ò ÌËÁÍÓÈ Ï‡ÒÒÓÈ
Ú·. ÇÓÁÏÓÊÌÓÈ Ô˘ËÌÓÈ ˝ÚÓ„Ó Ù‡ÍÚ‡ ÏÓ„ÎË ·˚Ú¸
ÔÂʉ‚ÂÏÂÌÌ˚ Ó‰˚. í‡Í, ‚ 22 ËÁ 31 ËÒÒΉӂ‡ÌËfl
·˚· ÓÚϘÂ̇ ÓÚˈ‡ÚÂθ̇fl Á‡‚ËÒËÏÓÒÚ¸ ÏÂÊ‰Û ÛÓ‚ÌflÏË „ÂÏÓ„ÎÓ·Ë̇ ËÎË „ÂχÚÓÍËÚÌÓ„Ó ˜ËÒ· Ë ‰ÎËÚÂθÌÓÒÚ¸˛ ·ÂÂÏÂÌÌÓÒÚË. ë‚flÁ¸ ÏÂÊ‰Û ÍÓ̈ÂÌÚ‡ˆËÂÈ
„ÂÏÓ„ÎÓ·Ë̇ Ë Ï‡ÒÒÓÈ Ú· ÌÓ‚ÓÓʉÂÌÌ˚ı ËÏÂÂÚ U-Ó·3
‡ÁÌ˚È ı‡‡ÍÚÂ, Ú.Â. ˜‡ÒÚÓÚ‡ ÓʉÂÌËfl ‰ÂÚÂÈ Ò ÌËÁÍÓÈ
χÒÒÓÈ Ú· ÔÓ‚˚¯‡ÂÚÒfl Í‡Í ÔË ÌËÁÍËı, Ú‡Í Ë ‚˚ÒÓÍËı
ÛÓ‚Ìfl „ÂÏÓ„ÎÓ·Ë̇ (˜ÚÓ ‚ ÔÓÒΉÌÂÏ ÒÎÛ˜‡Â, ÔÓ-‚ˉËÏÓÏÛ, ÓÚ‡Ê‡ÂÚ Ì‰ÓÒÚ‡ÚÓ˜ÌÓ ۂÂ΢ÂÌË ӷ˙Âχ ˆËÍÛÎËÛ˛˘ÂÈ Ô·ÁÏ˚).
êËÒÍ Ì··„ÓÔËflÚÌ˚ı ËÒıÓ‰Ó‚ Á‡‚ËÒËÚ ÓÚ ÚflÊÂÒÚË
‡ÌÂÏËË. ç‡ÔËÏÂ, S.Malhotra Ë ÒÓ‡‚Ú. [24] ËÁÛ˜‡ÎË ËÒıÓ‰˚ ·ÂÂÏÂÌÌÓÒÚË Û 447 ÊÂÌ˘ËÌ, ÍÓÚÓ˚ı ‡Á‰ÂÎËÎË
̇ 4 „ÛÔÔ˚ ‚ Á‡‚ËÒËÏÓÒÚË ÓÚ ÛÓ‚Ìfl „ÂÏÓ„ÎÓ·Ë̇ (ÓÚ
<7 ‰Ó >11 „/‰Î). ë‰Ìflfl χÒÒ‡ ÌÓ‚ÓÓʉÂÌÌ˚ı ‰ÂÚÂÈ
·˚· χÍÒËχθÌÓÈ Û ÊÂÌ˘ËÌ Ò ÛÓ‚ÌÂÏ „ÂÏÓ„ÎÓ·Ë̇
9,6-10,5 „/‰Î, ‡ ÏËÌËχθÌÓÈ - Û ÊÂÌ˘ËÌ Ò ÛÓ‚ÌÂÏ „ÂÏÓ„ÎÓ·Ë̇ <7 „/‰Î. íflÊ·fl ‡ÌÂÏËfl ‡ÒÒÓˆËËÓ‚‡Î‡Ò¸
Ú‡ÍÊÂ Ò Û‚Â΢ÂÌËÂÏ ‰ÎËÚÂθÌÓÒÚË Ó‰Ó‚ÓÈ ‰ÂflÚÂθÌÓÒÚË Ë ÌÂÓ·ıÓ‰ËÏÓÒÚË ‚ ÓÔÂ‡ÚË‚ÌÓÏ ‚ϯ‡ÚÂθÒÚ‚Â. èÓ
‰‡ÌÌ˚Ï K.Rasmussen [23], ÔË Ì‡Î˘ËË ‚˚‡ÊÂÌÌÓÈ
‡ÌÂÏËË (<8 „/‰Î) χÒÒ‡ Ú· ÌÓ‚ÓÓʉÂÌÌ˚ı ·˚· ‚ ˆÂÎÓÏ Ì‡ 200-400 „ ÌËÊÂ, ˜ÂÏ Û Ô‡ˆËÂÌÚÓÍ Ò ·ÓΠ‚˚ÒÓÍËÏË ÛÓ‚ÌflÏË „ÂÏÓ„ÎÓ·Ë̇ (>10 „/‰Î).
Ç ÌÂÍÓÚÓ˚ı ËÒÒΉӂ‡ÌËı ÒÔˆˇθÌÓ ËÁÛ˜‡ÎËÒ¸ Ì··„ÓÔËflÚÌ˚ ÔÓÒΉÒÚ‚Ëfl ÊÂÎÂÁÓ‰ÂÙˈËÚÌÓÈ ‡ÌÂÏËË.
ç‡ÔËÏÂ, ‚ ËÒÒΉӂ‡ÌËË T.Scholl Ë ÒÓ‡‚Ú. [25] ·ÓÎÂÂ
˜ÂÏ Û 800 ·ÂÂÏÂÌÌ˚ı ÊÂÌ˘ËÌ Ì‡Î˘Ë ÊÂÎÂÁÓ‰ÂÙˈËÚ‡ ‡ÒÒÓˆËËÓ‚‡ÎÓÒ¸ Ò Û‚Â΢ÂÌËÂÏ ÓÚÌÓÒËÚÂθÌÓ„Ó ËÒ͇ ÓʉÂÌËfl ‰ÂÚÂÈ Ò ÌËÁÍÓÈ Ï‡ÒÒÓÈ Ú· ‚ 3 ‡Á‡ Ë
ÔÂʉ‚ÂÏÂÌÌ˚ı Ó‰Ó‚ - ‚ 2 ‡Á‡, ‚ ÚÓ ‚ÂÏfl Í‡Í ‡ÌÂÏËfl ‰Û„ÓÈ ˝ÚËÓÎÓ„ËË Ì Ô˂Ӊ˷ Í ÔÓ‚˚¯ÂÌ˲ ˜‡ÒÚÓÚ˚ ÔÓ‰Ó·Ì˚ı ËÒıÓ‰Ó‚. ëıÓ‰Ì˚ ‰‡ÌÌ˚ ·˚ÎË
ÔÓÎÛ˜ÂÌ˚ Ë ‚ ÌÂÍÓÚÓ˚ı ‰Û„Ëı ËÒÒΉӂ‡ÌËflı. ç‡ÔËÏÂ, ‚ ëËÌ„‡ÔÛ ·˚ÎË ÔӇ̇ÎËÁËÓ‚‡Ì˚ ËÒıÓ‰˚ ·ÂÂÏÂÌÌÓÒÚË Û ÊÂÌ˘ËÌ, ÍÓÚÓ˚ ‚ 1993 „Ó‰‡ ÓʇÎË ‚
Ó‰ÌÓÏ Î˜·ÌÓÏ Û˜ÂʉÂÌËË [26]. ÄÌÂÏËfl ·˚· ‚˚fl‚ÎÂ̇ Û 15,3% ËÁ ÌËı. Ç ÔÓ‰‡‚Îfl˛˘ÂÏ ·Óθ¯ËÌÒÚ‚Â ÒÎÛ˜‡Â‚ (81,3%) Ó̇ ·˚· ÊÂÎÂÁÓ‰ÂÙˈËÚÌÓÈ. ç‡Î˘ËÂ
‡ÌÂÏËË ÒÓÔÓ‚Óʉ‡ÎÓÒ¸ Û‚Â΢ÂÌËÂÏ ˜‡ÒÚÓÚ˚ ÔÂʉ‚ÂÏÂÌÌ˚ı Ó‰Ó‚, ıÓÚfl ˜‡ÒÚÓÚ‡ ‰Û„Ëı Ì··„ÓÔËflÚÌ˚ı
ËÒıÓ‰Ó‚ ÒÛ˘ÂÒÚ‚ÂÌÌÓ Ì ËÁÏÂÌË·Ҹ.
àÌÚÂÔÂÚËÓ‚‡Ú¸ ÂÁÛθڇÚ˚ ËÒÒΉӂ‡ÌËÈ, ‚ ÍÓÚÓ˚ı ËÁÛ˜‡ÎÓÒ¸ ‚ÎËflÌË ‡ÌÂÏËË Ì‡ ËÒıÓ‰˚ ·ÂÂÏÂÌÌÓÒÚË, ‰ÓÒÚ‡ÚÓ˜ÌÓ ÒÎÓÊÌÓ, Ú‡Í Í‡Í ÏÌÓ„Ë ËÁ ÌËı ËÏÂÎË
ÒÛ˘ÂÒÚ‚ÂÌÌ˚ ӄ‡Ì˘ÂÌËfl Ò ÏÂÚÓ‰ÓÎӄ˘ÂÒÍÓÈ ÚÓ˜ÍË
ÁÂÌËfl. í˜ÂÌË ·ÂÂÏÂÌÌÓÒÚË Ë Â ËÒıÓ‰˚ Á‡‚ËÒflÚ ÌÂ
ÚÓθÍÓ ÓÚ Ì‡Î˘Ëfl ‡ÌÂÏËË ËÎË ÊÂÎÂÁÓ‰ÂÙˈËÚ‡, ÌÓ Ë
ÏÌÓ„Ëı Ù‡ÍÚÓÓ‚, Û˜ÂÒÚ¸ ÍÓÚÓ˚ ÒÎÓÊÌÓ. íÂÏ ÌÂ
ÏÂÌÂÂ, Ëϲ˘ËÂÒfl ‰‡ÌÌ˚ ‰ÓÒÚ‡ÚÓ˜ÌÓ Û·Â‰ËÚÂθÌÓ ‰ÂÏÓÌÒÚËÛ˛Ú ‡ÒÒӈˇˆË˛ ÏÂÊ‰Û ÍÓ̈ÂÌÚ‡ˆËÂÈ „ÂÏÓ„ÎÓ·Ë̇ Û ·ÂÂÏÂÌÌÓÈ ÊÂÌ˘ËÌ˚ Ë Ï‡ÒÒÓÈ Ú·
ÌÓ‚ÓÓʉÂÌÌ˚ı, ‡ Ú‡ÍÊ ËÒÍÓÏ ÔÂʉ‚ÂÏÂÌÌ˚ı Ó‰Ó‚ [25].
Лечение и профилактика анемии у беременных
èÓÒÚ˚Ï Ë ˝ÙÙÂÍÚË‚Ì˚Ï ÏÂÚÓ‰ÓÏ ÔÓÙË·ÍÚËÍË Ë Î˜ÂÌËfl ÊÂÎÂÁÓ‰ÂÙˈËÚÌÓÈ ‡ÌÂÏËË fl‚ÎflÂÚÒfl ÔÂÓ‡Î¸ÌÓÂ
ÔËÏÂÌÂÌË ÔÂÔ‡‡ÚÓ‚ ÊÂÎÂÁ‡. àı ËÒÔÓθÁÓ‚‡ÌË ‚Ó
‚ÂÏfl ·ÂÂÏÂÌÌÓÒÚË ÔË‚Ó‰ËÚ Í ÔÓ‚˚¯ÂÌ˲ ÛÓ‚ÌÂÈ
„ÂÏÓ„ÎÓ·Ë̇ Ë Ò˚‚ÓÓÚÓ˜ÌÓ„Ó ÙÂËÚË̇ Ë, ‚ÂÓflÚÌÓ,
4
ÒÔÓÒÓ·ÒÚ‚ÛÂÚ Û‚Â΢ÂÌ˲ Á‡Ô‡ÒÓ‚ ÊÂÎÂÁ‡ Û ÌÓ‚ÓÓʉÂÌÌÓ„Ó [27]. Ç ÂÍÓÏẨ‡ˆËflı Çéá Û͇Á‡ÌÓ [5], ˜ÚÓ ÔÓÙË·ÍÚ˘ÂÒÍÓ ÔËÏÂÌÂÌË ÔÂÔ‡‡ÚÓ‚ ÊÂÎÂÁ‡ (60 Ï„)
ÌÂÓ·ıÓ‰ËÏÓ ‚ÒÂÏ ·ÂÂÏÂÌÌ˚Ï ÊÂÌ˘Ë̇Ï. Ö„Ó ÌÂÓ·ıÓ‰ËÏÓ Ì‡˜Ë̇ڸ Í‡Í ÏÓÊÌÓ ‡Ì¸¯Â (Ì ÔÓÁ‰Ì ÚÂڸ„Ó
ÏÂÒflˆ‡) Ë ÔÓ‰ÓÎʇڸ ‰Ó ÍÓ̈‡ ·ÂÂÏÂÌÌÓÒÚË. Ç „ËÓ̇ı, „‰Â ˜‡ÒÚÓÚ‡ ÊÂÎÂÁÓ‰ÂÙˈËÚÌÓÈ ‡ÌÂÏËË, Ô‚˚¯‡ÂÚ
40%, ÔÓÙË·ÍÚ˘ÂÒÍËÈ ÔËÂÏ ÔÂÔ‡‡ÚÓ‚ ÊÂÎÂÁ‡ ÒΉÛÂÚ ÔÓ‰ÓÎʇڸ ‚ Ú˜ÂÌË ÔÓ Í‡ÈÌÂÈ ÏÂ 3 ÏÂÒflˆÂ‚
ÔÓÒΠÓ‰Ó‚. ÖÒÎË Û ÊÂÌ˘ËÌ˚ ËÏÂÂÚÒfl ‡ÌÂÏËfl, ÚÓ ÔÂÔ‡‡Ú˚ ÊÂÎÂÁ‡ ˆÂÎÂÒÓÓ·‡ÁÌÓ ÔËÏÂÌflÚ¸ ‚ Θ·ÌÓÈ ‰ÓÁ (120 Ï„).
ÑÓÒÚ‡ÚÓ˜ÌÓ ˝ÙÙÂÍÚË‚Ì˚ÏË, ‚ÂÓflÚÌÓ, ÏÓ„ÛÚ ·˚Ú¸ Ë
·ÓΠÌËÁÍË ÔÓÙË·ÍÚ˘ÂÒÍË ‰ÓÁ˚ ÊÂÎÂÁ‡. N.Milman
Ë ÒÓ‡‚Ú. [28] ‚ ‡Ì‰ÓÏËÁËÓ‚‡ÌÌÓÏ ‰‚ÓÈÌÓÏ ÒÎÂÔÓÏ ËÒÒΉӂ‡ÌËË ÒÓÔÓÒÚ‡‚ËÎË ÂÁÛθڇÚ˚ ÔËÏÂÌÂÌËfl ÔÂÔ‡‡Ú‡ ÊÂÎÂÁ‡ ‚ ‡Á΢Ì˚ı ‰ÓÁ‡ı, ÍÓÚÓ˚ ̇Á̇˜‡ÎË
ÔÓÒΠ18-È Ì‰ÂÎË ·ÂÂÏÂÌÌÓÒÚË 427 Á‰ÓÓ‚˚Ï ÊÂÌ˘Ë̇Ï. éÔÚËχθ̇fl ‰ÓÁ‡ ÒÓÒÚ‡‚Ë· 40 Ï„, Ú‡Í Í‡Í Ó̇
Ó·ÂÒÔ˜˂‡Î‡ ÔÓÙË·ÍÚËÍÛ ÊÂÎÂÁÓ‰ÂÙˈËÚ‡ Û 90% Ô‡ˆËÂÌÚÓÍ Ë ÊÂÎÂÁÓ‰ÂÙˈËÚÌÓÈ ‡ÌÂÏËË - Û 95%. èÓ ‰‡ÌÌ˚Ï ‰Û„Ó„Ó ‡Ì‰ÓÏËÁËÓ‚‡ÌÌÓ„Ó ËÒÒΉӂ‡ÌËfl Û 430
ÊÂÌ˘ËÌ [29], ‰ÓÒÚ‡ÚÓ˜Ì˚Ï ÏÓÊÂÚ ·˚Ú¸ ‰‡Ê ÔËÂÏ 20
Ï„ ÊÂÎÂÁ‡, ̇˜Ë̇fl Ò 20-È Ì‰ÂÎË ·ÂÂÏÂÌÌÓÒÚË. èÓ‰Ó·Ì˚ ËÒÒΉӂ‡ÌËfl Ô‰ÒÚ‡‚Îfl˛Ú ÌÂÒÓÏÌÂÌÌ˚È ËÌÚÂÂÒ,
Ú‡Í Í‡Í ÒÌËÊÂÌË ‰ÓÁ˚ ÔÂÔ‡‡ÚÓ‚ ÊÂÎÂÁ‡ ÔÓÁ‚ÓÎflÂÚ
ÛÎÛ˜¯ËÚ¸ Ëı ÔÂÂÌÓÒËÏÓÒÚ¸.
ç‡Ë·ÓΠ۷‰ËÚÂθÌ˚Ï ÔÓ‰Ú‚ÂʉÂÌËÂÏ Ì··„ÓÔËflÚÌÓ„Ó ‚ÎËflÌËfl ÊÂÎÂÁÓ‰ÂÙˈËÚ‡ Ë ‡ÌÂÏËË Ì‡ Ú˜ÂÌËÂ Ë ËÒıÓ‰˚ ·ÂÂÏÂÌÌÓÒÚË ÏÓ„ÎË ·˚ ÒÎÛÊËÚ¸
ÂÁÛθڇÚ˚ ‡Ì‰ÓÏËÁËÓ‚‡ÌÌ˚ı ÍÓÌÚÓÎËÛÂÏ˚ı ËÒÒΉӂ‡ÌËÈ, ‰ÂÏÓÌÒÚËÛ˛˘Ëı ˝ÙÙÂÍÚË‚ÌÓÒÚ¸ ÔÂÔ‡‡ÚÓ‚
ÊÂÎÂÁ‡. Ç ÔÓÒΉÌË ‰ÂÒflÚËÎÂÚËfl ÔÓ‰Ó·Ì˚ ÔÓÔ˚ÚÍË
Ô‰ÔËÌËχÎËÒ¸ ÌÂÓ‰ÌÓÍ‡ÚÌÓ. ç‡ÔËÏÂ, M.Cogswell
Ë ÒÓ‡‚Ú. [30] ÒÓÔÓÒÚ‡‚ËÎË ÂÁÛθڇÚ˚ ÔËÏÂÌÂÌËfl ÔÂÔ‡‡Ú‡ ÊÂÎÂÁ‡ (30 Ï„/ÒÛÚ) Ë Ô·ˆÂ·Ó ‚ Ú˜ÂÌË ÔÂ‚˚ı 28
̉Âθ ·ÂÂÏÂÌÌÓÒÚË Û 275 ÊÂÌ˘ËÌ. ïÓÚfl Ôӂ‰ÂÌ̇fl
ÚÂ‡ÔËfl Ì ÔÓ‚ÎËfl· ̇ ˜‡ÒÚÓÚÛ ‡Á‚ËÚËfl ‡ÌÂÏËfl ËÎË
ÔÂʉ‚ÂÏÂÌÌ˚ı Ó‰Ó‚, Ӊ̇ÍÓ Ó̇ ÒÓÔÓ‚Óʉ‡Î‡Ò¸
Á̇˜ËÚÂθÌ˚Ï ÒÌËÊÂÌËÂÏ ˜‡ÒÚÓÚ˚ ÓʉÂÌËfl ‰ÂÚÂÈ Ò
ÌËÁÍÓÈ Ï‡ÒÒÓÈ Ú· (4 Ë 17%; =0,003) Ë Ì‰ÓÌÓ¯ÂÌÌ˚ı
‰ÂÚÂÈ Ò ÌËÁÍÓÈ Ï‡ÒÒÓÈ Ú· (3 Ë 10%; =0,017). K.Cuervo
Ë K.Mahomed [31] ÔÓ‚ÂÎË ÒËÒÚÂχÚËÁËÓ‚‡ÌÌ˚È Ó·ÁÓ
‚ÒÂı ËÒÒΉӂ‡ÌËÈ, ‚ ÍÓÚÓ˚ı ËÁÛ˜‡Î‡Ò¸ ˝ÙÙÂÍÚË‚ÌÓÒÚ¸
ΘÂÌËfl ÊÂÎÂÁÓ‰ÂÙˈËÚÌÓÈ ‡ÌÂÏËË ‚Ó ‚ÂÏfl ·ÂÂÏÂÌÌÓÒÚË ‚ ÔÓÙË·ÍÚËÍ Á‡·Ó΂‡ÂÏÓÒÚË Ë ÒÏÂÚÌÓÒÚË Û
ÊÂÌ˘ËÌ Ë ÌÓ‚ÓÓʉÂÌÌ˚ı. ÇÒÂ„Ó ·˚ÎË Ì‡È‰ÂÌ˚ 54
Ú‡ÍËı ËÒÒΉӂ‡ÌËfl, Ӊ̇ÍÓ ÚÓθÍÓ 5 ËÁ ÌËı ÒÓÓÚ‚ÂÚÒÚ‚Ó‚‡ÎË ÍËÚÂËflÏ ÓÚ·Ó‡, ‡ ÓÒڇθÌ˚ ËÏÂÎË ÒÛ˘ÂÒÚ‚ÂÌÌ˚ Ì‰ÓÒÚ‡ÚÍË. Ä‚ÚÓ˚ Ì ӷ̇ÛÊËÎË Ò‚Â‰ÂÌËÈ Ó·
ÛÎÛ˜¯ÂÌËË ËÒıÓ‰Ó‚ ·ÂÂÏÂÌÌÓÒÚË. R.Rasmussen [25],
ÔӇ̇ÎËÁËÓ‚‡‚¯‡fl 17 ËÒÒΉӂ‡ÌËÈ, Ú‡ÍÊ ÓÚÏÂÚË·
ÌËÁÍÓ Ëı ͇˜ÂÒÚ‚Ó Ò ÏÂÚÓ‰ÓÎӄ˘ÂÒÍÓÈ ÚÓ˜ÍË ÁÂÌËfl,
Ì ÔÓÁ‚ÓÎfl‚¯Â ҉·ڸ ͇ÍËÂ-ÎË·Ó ÓÔ‰ÂÎÂÌÌ˚ ‚˚‚Ó‰˚. ëΉÛÂÚ ÔÓ‰˜ÂÍÌÛÚ¸, ˜ÚÓ ıÓÚfl ‚ Û͇Á‡ÌÌ˚ı ËÒÒΉӂ‡ÌËÈ Ì ۉ‡ÎÓÒ¸ ۷‰ËÚÂθÌÓ ‰Ó͇Á‡Ú¸ ÔÓθÁÛ
КЛИНИЧЕСКАЯ ФАРМАКОЛОГИЯ И ТЕРАПИЯ, 2005, 14 (2)
100
80
60
40
20
0
跈·Ó
ÇËÚ‡ÏËÌ Ä
ÜÂÎÂÁÓ
ÇËÚ‡ÏËÌ Ä +
ÊÂÎÂÁÓ
Рис. 2. Частота нормализации уровня гемоглобина при
лечении витамином А, препаратом железа и их комбинацией у беременных женщин с анемией
ÔËÏÂÌÂÌËfl ÔÂÔ‡‡ÚÓ‚ ÊÂÎÂÁ‡ Ò ˆÂθ˛ ÛÎÛ˜¯ÂÌËfl ËÒıÓ‰Ó‚ ·ÂÂÏÂÌÌÓÒÚË, Ӊ̇ÍÓ Ó̇ Ë Ì ·˚· ÓÚ‚Â„ÌÛÚ‡.
ëÓÓÚ‚ÂÚÒÚ‚ÂÌÌÓ, Ô˂‰ÂÌÌ˚ ‰‡ÌÌ˚ Ì fl‚Îfl˛ÚÒfl ÓÒÌÓ‚‡ÌËÂÏ ‰Îfl ÓÚ͇Á‡ ÓÚ ÒÛ˘ÂÒÚ‚Û˛˘ÂÈ Ô‡ÍÚËÍË ÔÓÙË·ÍÚ˘ÂÒÍÓ„Ó ËÒÔÓθÁÓ‚‡ÌËfl ÔÓ‰Ó·Ì˚ı Ò‰ÒÚ‚ Û
·ÂÂÏÂÌÌ˚ı ÊÂÌ˘ËÌ.
è˘ËÌÓÈ ‡ÌÂÏËË Û ·ÂÂÏÂÌÌÓÈ ÊÂÌ˘ËÌ˚ ÏÓÊÂÚ
·˚Ú¸ ‰ÂÙˈËÚ Ì ÚÓθÍÓ ÊÂÎÂÁ‡, ÌÓ Ë ÙÓÎË‚ÓÈ ÍËÒÎÓÚ˚. ëÓÓÚ‚ÂÚÒÚ‚ÂÌÌÓ, ‰Ó·‡‚ÎÂÌË ÙÓÎË‚ÓÈ ÍËÒÎÓÚ˚ Í
ÔÂÔ‡‡ÚÛ ÊÂÎÂÁ‡ ÏÓÊÂÚ ÔÓ‚˚ÒËÚ¸ ˝ÙÙÂÍÚË‚ÌÓÒÚ¸ ΘÂÌËfl Ë ÔÓÙË·ÍÚËÍË ‡ÌÂÏËË. Ç ÏÌÓ„ÓˆÂÌÚÓ‚ÓÏ, ‰‚ÓÈÌÓÏ ÒÎÂÔÓÏ ‡Ì‰ÓÏËÁËÓ‚‡ÌÌÓÏ ËÒÒΉӂ‡ÌËË Û 371
·ÂÂÏÂÌÌÓÈ ÊÂÌ˘ËÌ˚ Ò ÊÂÎÂÁÓ‰ÂÙˈËÚÌÓÈ ‡ÌÂÏËÂÈ
·˚· ÒÓÔÓÒÚ‡‚ÎÂ̇ ˝ÙÙÂÍÚË‚ÌÓÒÚ¸ ÏÓÌÓÚÂ‡ÔËË ÔÂÔ‡‡ÚÓÏ ÊÂÎÂÁ‡ (80 Ï„) Ë Â„Ó ÍÓÏ·Ë̇ˆËË Ò ÙÓÎË‚ÓÈ ÍËÒÎÓÚÓÈ (0,370 Ï„) [32]. ç‡ ÙÓÌ ÍÓÏ·ËÌËÓ‚‡ÌÌÓÈ
ÚÂ‡ÔËË ÛÓ‚Â̸ „ÂÏÓ„ÎÓ·Ë̇ Û‚Â΢ËÎÒfl ‚ ·Óθ¯ÂÈ
ÒÚÂÔÂÌË, ˜ÂÏ ÔË ÔËÂÏ ÚÓθÍÓ ÔÂÔ‡‡Ú‡ ÊÂÎÂÁ‡
(p<0,001). ÅÓΠÚÓ„Ó, ÔËÏÂÌÂÌË ÙÓÎË‚ÓÈ ÍËÒÎÓÚ˚ ‚
ÔÂËÓ‰ Á‡˜‡ÚËfl ÔË Ô·ÌËÛÂÏÓÈ ·ÂÂÏÂÌÌÓÒÚË ÔË‚Ó‰ËÚ Í ‰ÓÒÚÓ‚ÂÌÓÏÛ ÒÌËÊÂÌ˲ ˜‡ÒÚÓÚ˚ ‚ÓʉÂÌÌ˚ı ÔÓÓÍÓ‚ ÌÂ‚ÌÓÈ ÚÛ·ÍË. èÓ ‰‡ÌÌ˚Ï ÏÂÚ‡-‡Ì‡ÎËÁ‡ 4
ËÒÒΉӂ‡ÌËÈ Û 6425 ÊÂÌ˘ËÌ [33], ˜‡ÒÚÓÚ‡ Ú‡ÍËı ÔÓÓÍÓ‚ ÒÌËÁË·Ҹ ̇ 72%.
èËÏÂÌÂÌË ‰Û„Ëı ‚ËÚ‡ÏËÌÓ‚ Ú‡ÍÊ ÏÓÊÂÚ ÒÔÓÒÓ·ÒÚ‚Ó‚‡Ú¸ ÛÎÛ˜¯ÂÌ˲ ÂÁÛθڇÚÓ‚ ΘÂÌËfl ‡ÌÂÏËË Û ·ÂÂÏÂÌÌ˚ı ÊÂÌ˘ËÌ. D.Suharno Ë ÒÓ‡‚Ú. [34] ‚ ‰‚ÓÈÌÓÏ
ÒÎÂÔÓÏ, Ô·ˆÂ·Ó-ÍÓÌÚÓÎËÛÂÏÓÏ ËÒÒΉӂ‡ÌËË Û 251
·ÂÂÏÂÌÌÓÈ ÊÂÌ˘ËÌ˚ Ò ‡ÌÂÏËÂÈ ÒÓÔÓÒÚ‡‚ËÎË ˝ÙÙÂÍÚË‚ÌÓÒÚ¸ ÚÂ‡ÔËË ‚ËÚ‡ÏËÌÓÏ Ä (2,4 Ï„) Ë/ËÎË ÔÂÔ‡‡ÚÓÏ ÊÂÎÂÁ‡ (60 Ï„). ÑÓÎfl ÊÂÌ˘ËÌ, Û ÍÓÚÓ˚ı Û‰‡ÎÓÒ¸
‰Ó·ËÚ¸Òfl ÌÓχÎËÁ‡ˆËË ÛÓ‚Ìfl „ÂÏÓ„ÎÓ·Ë̇, ·˚·
χÍÒËχθÌÓÈ ÔË ÔËÏÂÌÂÌËË ÔÂÔ‡‡Ú‡ ÊÂÎÂÁ‡ ‚
ÒÓ˜ÂÚ‡ÌËË Ò ‚ËÚ‡ÏËÌÓÏ Ä (ËÒ. 2). äÓÏ ÚÓ„Ó, ‚ËÚ‡ÏËÌ˚ Ë ÏËÌÂ‡Î˚ ÏÓ„ÛÚ ‰‡‚‡Ú¸ Ë ‰Û„Ë ·Î‡„ÓÔËflÚÌ˚Â
˝ÙÙÂÍÚ˚ ÔË ·ÂÂÏÂÌÌÓÒÚË. ç‡ÔËÏÂ, ÔÓ ‰‡ÌÌ˚Ï ÒËÒÚÂχÚËÁËÓ‚‡ÌÌÓ„Ó Ó·ÁÓ‡ ‡Ì‰ÓÏËÁËÓ‚‡ÌÌ˚ı ÍÓÌÚÓÎËÛÂÏ˚ı ËÒÒΉӂ‡ÌËÈ [35], ÔÂÔ‡‡Ú˚ ͇θˆËfl
ÒÌËʇÎË ˜‡ÒÚÓÚÛ Ô½Í·ÏÔÒËË Ë ‡ÚÂˇθÌÓÈ „ËÔÂКЛИНИЧЕСКАЯ ФАРМАКОЛОГИЯ И ТЕРАПИЯ, 2005, 14 (2)
ÚÓÌËË, ‡ ‚ËÚ‡ÏËÌ Ä Ë ·ÂÚ‡-͇ÓÚËÌ - χÚÂËÌÒÍÛ˛
ÒÏÂÚÌÓÒÚ¸. ùÚË ‰‡ÌÌ˚ ӷÓÒÌÓ‚˚‚‡˛Ú ÒÛ˘ÂÒÚ‚Û˛˘Û˛
Ô‡ÍÚËÍÛ ¯ËÓÍÓ„Ó ÔËÏÂÌÂÌËfl ÔÓÎË‚ËÚ‡ÏËÌÌ˚ı ÔÂÔ‡‡ÚÓ‚, ÒÓ‰Âʇ˘Ëı ÏËÍÓ˝ÎÂÏÂÌÚ˚, Û ·ÂÂÏÂÌÌ˚ı
ÊÂÌ˘ËÌ. ä ÒÓʇÎÂÌ˲, ˝ÙÙÂÍÚË‚ÌÓÒÚ¸ ÍÓÌÍÂÚÌ˚ı ÔÓÎË‚ËÚ‡ÏËÌÓ‚ ‰ÓÒÚ‡ÚÓ˜ÌÓ ‰ÍÓ ËÁÛ˜‡ÂÚÒfl ‚ ÍÓÌÚÓÎËÛÂÏ˚ı ÍÎËÌ˘ÂÒÍËı ËÒÒΉӂ‡ÌËflı, ıÓÚfl ÓÌË
Ô‰ÒÚ‡‚Îfl˛Ú ËÌÚÂÂÒ, Ú‡Í Í‡Í ÒÎÓÊÌÓÒÚ¸ ÒÓÒÚ‡‚‡ ÚÂÓÂÚ˘ÂÒÍË ÏÓÊÂÚ ÓÚ‡ÁËÚ¸Òfl ̇ ·ËÓ‰ÓÒÚÛÔÌÓÒÚË ÓÚ‰ÂθÌ˚ı
ÍÓÏÔÓÌÂÌÚÓ‚.
é‰ÌËÏ ËÁ ËÒÍβ˜ÂÌËÈ fl‚ÎflÂÚÒfl ÍÓÌÚÓÎËÛÂÏÓ ËÒÒΉӂ‡ÌËÂ, Ôӂ‰ÂÌÌÓ ‚ ÇÂÌ„ËË [36]. Ç ÌÂÏ ËÁÛ˜‡Î‡Ò¸ ˝ÙÙÂÍÚË‚ÌÓÒÚ¸ ù΂ËÚ‡ èÓ̇ڇθ, ÒÓ‰Âʇ˘Â„Ó
12 ‚ËÚ‡ÏËÌÓ‚, ‚Íβ˜‡fl 800 Ï„ ÙÓÎË‚ÓÈ ÍËÒÎÓÚ˚, 4 ÏËÌÂ‡Î‡ Ë 3 ÏËÍÓ˝ÎÂÏÂÌÚ‡, ‚ ÔÓÙË·ÍÚËÍ ÔÓÓÍÓ‚
ÌÂ‚ÌÓÈ ÚÛ·ÍË Û ÌÓ‚ÓÓʉÂÌÌ˚ı. ÜÂÌ˘Ë̇Ï, Ô·ÌËÛ˛˘ËÏ ·ÂÂÏÂÌÌÓÒÚ¸, ̇Á̇˜‡ÎË ù΂ËÚ èÓ̇ڇθ
ËÎË “Ô·ˆÂ·Ó” (ÚË ÏËÍÓ˝ÎÂÏÂÌÚ‡ Ë ‚ËÚ‡ÏËÌ ë ‚
Ó˜Â̸ ÌËÁÍÓÈ ‰ÓÁÂ) ÔÓ Í‡ÈÌÂÈ ÏÂ Á‡ 1 ÏÂÒflˆ ‰Ó Á‡˜‡ÒÚËfl. ÅÂÂÏÂÌÌÓÒÚ¸ ·˚· ÔÓ‰Ú‚ÂʉÂ̇ Û 4753 ÊÂÌ˘ËÌ.
ó‡ÒÚÓÚ‡ ‚ÓʉÂÌÌ˚ı ÔÓÓÍÓ‚ ‚ ÓÒÌÓ‚ÌÓÈ „ÛÔÔ ·˚·
Á̇˜ËÚÂθÌÓ ÌËÊÂ, ˜ÂÏ ‚ ÍÓÌÚÓθÌÓÈ (13,3 Ë 22,9 ̇
1000 ÒÓÓÚ‚ÂÚÒÚ‚ÂÌÌÓ, =0,02). èÓÓÍË ÌÂ‚ÌÓÈ ÚÛ·ÍË
·˚ÎË Á‡„ËÒÚËÓ‚‡Ì˚ Û 0 Ë 6 ÌÓ‚ÓÓʉÂÌÌ˚ı ÒÓÓÚ‚ÂÚÒÚ‚ÂÌÌÓ (=0,029). ëΉÛÂÚ ÓÚÏÂÚËÚ¸, ˜ÚÓ ‚ ÒÓÒÚ‡‚ ù΂ËÚ‡ èÓ̇ڇθ ‚ıÓ‰ËÚ ÊÂÎÂÁÓ ‚ ‰ÓÁÂ, ÂÍÓÏẨÛÂÏÓÈ
Çéá ‰Îfl ÔÓÙË·ÍÚËÍË ‡ÌÂÏËË (60 Ï„), ‡ Ú‡ÍÊ ‚ËÚ‡ÏËÌ˚ Ä Ë ë, ÒÔÓÒÓ·ÒÚ‚Û˛˘ËÂ Â„Ó ÛÒ‚ÓÂÌ˲. ùÚÓ ÔÓÁ‚ÓÎflÂÚ ÂÍÓÏẨӂ‡Ú¸ Â„Ó ÔËÏÂÌÂÌË ‚Ó ‚ÂÏfl
·ÂÂÏÂÌÌÓÒÚË Ë ÔÓÒΠÓ‰Ó‚ ‰Îfl ÔÓÙË·ÍÚËÍË Ë Î˜ÂÌËfl ‡ÌÂÏËË (ÔË Ì‡Î˘ËË ‚˚‡ÊÂÌÌÓÈ ‡ÌÂÏËË ÔÓ͇Á‡Ì
Ó‰ÌÓ‚ÂÏÂÌÌ˚È ÔËÂÏ ÔÂÔ‡‡ÚÓ‚ ÊÂÎÂÁ‡).
Заключение
ÄÌÂÏËfl fl‚ÎflÂÚÒfl ˜‡ÒÚ˚Ï Ë ÒÂ¸ÂÁÌ˚Ï ÓÒÎÓÊÌÂÌËÂÏ ·ÂÂÏÂÌÌÓÒÚË. é̇ Ó͇Á˚‚‡ÂÚ Ì··„ÓÔËflÚÌÓ ‚ÎËflÌËÂ
̇ ÒÓÒÚÓflÌË χÚÂË Ë ÔÎÓ‰‡ Ë ÛıÛ‰¯‡ÂÚ ËÒıÓ‰˚ ·ÂÂÏÂÌÌÓÒÚË. ó‡˘Â ‚ÒÂ„Ó Ô˘ËÌÓÈ ‡ÌÂÏËË Û ·ÂÂÏÂÌÌ˚ı
ÊÂÌ˘ËÌ Ó͇Á˚‚‡ÂÚ ÊÂÎÂÁÓ‰ÂÙˈËÚ, ÔÓ˝ÚÓÏÛ ˝ÙÙÂÍÚË‚Ì˚Ï ÏÂÚÓ‰ÓÏ ÔÓÙË·ÍÚËÍË Ë Î˜ÂÌËfl ˝ÚÓ„Ó ÒÓÒÚÓflÌËfl
ÒÎÛÊËÚ ÔËÏÂÌÂÌË ÔÂÔ‡‡ÚÓ‚ ÊÂÎÂÁ‡. ꇈËÓ̇θÌ˚Ï
ÔÓ‰ıÓ‰ÓÏ Í ÔÓÙË·ÍÚËÍ ‡ÌÂÏËË ‚Ó ‚ÂÏfl ·ÂÂÏÂÌÌÓÒÚË fl‚ÎflÂÚÒfl ‰ÎËÚÂθÌ˚È ÔËÂÏ ÔÓÎË‚ËÚ‡ÏËÌÌ˚ı ÔÂÔ‡‡ÚÓ‚, ÒÓ‰Âʇ˘Ëı ÏËÌÂ‡Î˚, ÍÓÚÓ˚È ÔÓÁ‚ÓÎflÂÚ
‚ÓÒÔÓÎÌËÚ¸ ‰ÂÙˈËÚ Ì ÚÓθÍÓ ÊÂÎÂÁ‡, ÌÓ Ë ‰Û„Ëı ‚¢ÂÒÚ‚, ÌÂÓ·ıÓ‰ËÏ˚ı ÊÂÌ˘ËÌ ‰Îfl ÌÓχθÌÓ„Ó Ú˜ÂÌËfl
·ÂÂÏÂÌÌÓÒÚË Ë ‡Á‚ËÚËfl ÔÎÓ‰‡.
1.
2.
3.
4.
5.
World Health Organization. The prevalence of anaemia in women: a tabulation of
available information. 2nd ed. Geneva: World Health Organization, 1992.
Sifakis S., Pharmakides G. Anemia in pregnancy. Ann. N. Y. Acad. Sci., 2000,
900, 125-136.
Massot C., Vanderpas J. A survey of iron deficiency anaemia during pregnancy in
Belgium: analysis of routine hospital laboratory data in Mons. Acta Clin. Belg.,
2003, 58 (3), 169-177.
Liao Q. and Chinese Children, Pregnant Women & Premenopausal Women Iron
Deficiency Epidemiological Survey Group. [Prevalence of iron deficiency in pregnant and premenopausal women in China: a nationwide epidemiological survey.]
Zhonghua Xue Ye Xue Za Zhi., 2004, 25 (11), 653-657.
Iron Deficiency Anaemia Assessment, Prevention, and Control. A guide for pro-
5
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
6
gramme managers. WHO, 2001.
U.S Department of Health and Human Services, Centers for Disease Control.
Current trends CDC criteria for anemia in children and childbearing-aged women.
MMWR, 1989, 38 (22), 400-404.
Carriaga M. et al. Serum transferrin receptor for the detection of iron deficiency
in pregnancy. Amer. J. Clin. Nutrition, 1991, 54, 1077-1081.
Bothwell T. Iron requirements in pregnancy and strategies to meet them. Am. J.
Clin. Nutr., 2000, 7 (suppl.), 257S-264S.
Cook J., Skikine B., Lynch S., Reusser M. Estimates of iron sufficiency in the US
population. Blood, 1986, 68, 726-731.
Hallberg L. Iron balance in pregnancy and lactation. In: Foman S., Sloukin S.,
eds. Nutritional anemias. New York: Raven Press, 1992, 13-28.
Rao R., Georgieff M. Perinatal aspects of iron metabolism. Acta Paediatr. Suppl.,
2002, 91 (438), 124-129.
Barker D., Gluckman P., Godfrey K. et al. Fetal nutrition and cardiovascular disease in adult life. Lancet, 1993, 341 (8850), 938-941.
Barker D. The developmental origins of adult disease. J. Amer. Coll. Nutrition,
2004, 23, 588S-595S.
Lau C., Rogers J. Embryonic and fetal programming of physiological disorders in
adulthood. Birth Defects Res. C Embryo. Today, 2004, 72 (4), 300-312.
Osmond C., Barker D., Winter P. et al. Early growth and death from cardiovascular disease in women. BMJ, 1993, 307, 1519-1524.
Hales C., Barker D., Clark P. et al. Fetal and infant growth and impaired glucose
tolerance at age 64. BMJ, 1991, 303, 1019-1022.
Huxley R., Collins R. Birth weight and subsequent cholesterol levels. Exploration
of the "fetal origins" hypothesis. JAMA, 2004, 292, 2755-2764.
Oken E., Gillman M. Fetal origins of obesity. Obes. Res., 2003, 11, 496-506.
Mahajan S., Singh S., Shah P. et al. Effect of maternal malnutrition and anemia
on the endocrine regulation of fetal growth. Endocr. Res., 2004, 30 (2), 189-203.
Allen L. Biological mechanisms that might underlie iron's effects on fetal growth
and preterm birth. J. Nutr., 2001, 131, 581S-589S.
Brabin B., Hakimi M., Pelletier D. An analysis of anemia and pregnancy-related
maternal mortality. J. Nutr., 2001, 131, 604S-615S.
Chi I., Agoestina T., Harbin J. Maternal mortality at twelve teaching hospitals in
Indonesia -an epidemiologic analysis. Int. J. Gynaecol. Obstet., 1981, 19, 259-266
Rassmussen K. Is there a causal relationship between iron deficiency or iron-deficiency anemia and weight at birth, length of gestation and perinatal mortality? J.
Nutr., 2001, 131, 590S-603S.
24. Malhotra M., Sharma J., Batra S. et al. Maternal and perinatal outcome in varying degrees of anemia. Int. J. Gynaecol. Obstet., 2002, 79 (2), 93-100.
25. Scholl T., Hediger M., Fischer R., Shearer J. Anemia vs iron deficiency: increased
risk of preterm delivery in a prospective study. Am. J. Clin. Nutr., 1992, 55 (5),
985-958.
26. Singh K., Fong Y., Arulkumaran S. Anaemia in pregnancy--a cross-sectional
study in Singapore. Eur. J. Clin. Nutr., 1998, 52 (1), 65-70.
27. Mungen E. Iron supplementation in pregnancy. J. Perinat. Med., 2003, 31 (5),
420-426.
28. Milman N., Bergholt T., Eriksen L. et al. Iron prophylaxis during pregnancy How much iron is needed? A randomized dose- response study of 20-80 mg ferrous iron daily in pregnant women. Acta Obstet. Gynecol. Scand., 2005, 84 (3),
238-247.
29. Makrides M., Crowther C., Gibson R. et al. fficacy and tolerability of low-dose
iron supplements during pregnancy: a randomized controlled trial. Am. J. Clin.
Nutr., 2003, 78 (1), 145-153.
30. Cogswell M., Parvanta I., Ickes L. et al. Iron supplementation during pregnancy,
anemia, and birth weight: a randomized controlled trial. Am. J. Clin. Nutr., 2003,
78 (4), 773-781.
31. Cuervo L., Mahomed K. Treatments for iron deficiency anaemia in pregnancy.
Cochrane Database Syst. Rev., 2001, 2, CD003094.
32. Juarez-Vazquez J., Bonizzoni E., Scotti A. Iron plus folate is more effective than
iron alone in the treatment of iron deficiency anaemia in pregnancy: a randomised, double blind clinical trial. BJOG, 2002, 109 (9), 1009-1014.
33. Lumley J., Watson L., Watson M., Bower C. Periconeptional supplementation
with folate and/or multivitamins for preventing neural tube defects (Cochrane
Review). Cochrane Database Syst. Rev., 2001, 3, CD001056.
34. Suharno D., West C., Muhilal K. et al. Supplementation with vitamin A and iron
for nutritional anaemia in pregnant women in West Java, Indonesia. Lancet, 1993,
342, 1325-1328.
35. Villar J., Merialdi M., Guimezoglu A. et al. Nutritional interventions during pregnancy for the prevention or treatment of maternal morbidity and preterm delivery:
An overview of randomized controlled trials. J. Nutr., 2003, 133, 1606S-1625S.
36. Czeizel A., Dudas I. Prevention of the first occurrence of neural-tube defects by
periconceptional vitamin supplementation. N. Engl. J. Med., 1992, 327 (26),
1832-1835.
КЛИНИЧЕСКАЯ ФАРМАКОЛОГИЯ И ТЕРАПИЯ, 2005, 14 (2)
Скачать